Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897358 · ClinicalTrials.gov registry record · Phase 2
Leniolisib for Immune Dysregulation in CVID
A Phase 2 study of Common Variable Immunodeficiency (CVID), sponsored by Pharming Technologies B.V..
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06897358 is a Phase 2 study of Common Variable Immunodeficiency (CVID) that is active but no longer recruiting, run by Pharming Technologies B.V.. The registered enrollment target is 20 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT06897358, a Phase 2 study of Common Variable Immunodeficiency (CVID), is active but no longer recruiting, sponsored by Pharming Technologies B.V..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Conditions Studied
Interventions
- DRUG Leniolisib
Study Locations (7)
Other
- IIS La Fe - Valencia
- Leeds Teaching Hospital NHS Trust - Leeds
Colorado
- Children's Hospital Colorado - Aurora
Maryland
- National Institute of Health - Bethesda
Massachusetts
- Lahey Hospital & Medical Center - Burlington
New York
- Mount Sinai Hospital - New York
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06897358
The ClinicalTrials.gov registry entry for NCT06897358 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharming Technologies B.V., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Common Variable Immunodeficiency (CVID) appearing as the primary indexed condition, and to 1 intervention - of which Leniolisib is the first listed.
NCT06897358 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT06897358 about?
NCT06897358 is a clinical study titled "Leniolisib for Immune Dysregulation in CVID". In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerab...
What is the current status of trial NCT06897358?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-12. Estimated completion is 2026-10.
What conditions does trial NCT06897358 study?
This clinical trial studies the following conditions: Common Variable Immunodeficiency (CVID).
What interventions are being tested in trial NCT06897358?
The interventions under investigation include: Leniolisib (DRUG).
Who is sponsoring clinical trial NCT06897358?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06897358 being conducted?
This trial has 7 study locations across Colorado, Maryland, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Variable Immunodeficiency (CVID)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.